M.S. has received research support and honoraria from Janssen, Bristol Myers Squibb, Ipsen, MSD, Astellas and Bayer, all unrelated to the present paper. F.M. has received research support and/or honoraria from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, BMS, Janssen, Ipsen, MSD and Pfizer outside the submitted work. L.C. has received honoraria for advisory boards, speaker engagements and scientific consultancy for educational purposes from AstraZeneca, EISAI, MSD, Ipsen, BMS and A.A.A., and is a past MSD employee in Medical Affairs. O.F. received honoraria from Novartis, Janssen, Merck and Pfizer for consultations and lectures unrelated to this project. S.B. has received honoraria for speaking at scientific events and advisory roles from AstraZeneca, Bristol Myers Squibb, Ipsen, Merck, Eisai, MSD, Novartis and Pfizer, and research funding from Novartis and Pfizer. J.B. reports institutional and personal, paid and unpaid support for research, advisory boards, consultancy and honoraria (all outside this work) from AstraZeneca, Bristol Myers-Squibb, EMD Serono, Merck, Pfizer, Roche, Sanofi/Aventis, Up-To-Date and CME events (Peerview, OncLive), outside the submitted work; no speaker’s bureau. The other authors declare no competing interests.